Skip to content

GLP-1 news: where the new GLP-1 drugs stand with FDA

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

A common question in GLP-1 news is whether retatrutide is approved. It isn't. Retatrutide and CagriSema are investigational and not FDA-approved. Lilly has said it plans to submit retatrutide to FDA in the first quarter of 2027. Novo Nordisk filed CagriSema in December 2025 and has said a decision is expected in the fourth quarter of 2026. Orforglipron was approved as Foundayo on April 1, 2026.

Source: Eli Lilly

Key takeaways

  • Retatrutide and CagriSema are not FDA-approved. Outside a clinical trial, you can't be prescribed either one.
  • Lilly's 2027 plan is to submit retatrutide for review. A submission is not an approval.
  • FDA says retatrutide and cagrilintide cannot be used in compounding, and "research use" sales are illegal.
  • Trial figures in press releases come from the companies, not from FDA.
  • Orforglipron is now approved for weight management as Foundayo, with a label and published prices.

New obesity medicines make headlines long before anyone can be prescribed them. This page covers the two people ask about most, retatrutide and CagriSema, plus two that have moved from pipeline to pharmacy. For each one, you’ll find its standing with FDA and the results the company has published. All of it comes from company announcements, FDA and ClinicalTrials.gov, quoted in the sources below.

Two rules apply to everything here. First, company press releases report results in the company’s own words, and they are not FDA findings. Second, a planned submission or an expected decision date is a statement about timing. It is not a forecast of approval, and we don’t predict approval dates.

What does “investigational” mean for you?

It means you can’t be prescribed the medicine outside a clinical trial. An investigational medicine has no FDA label, no approved dose, no pharmacy supply and no price. Lilly’s own wording for retatrutide is that it “cannot be legally sold or marketed for human use.”

It also means the evidence isn’t finished. Lilly’s statement lists what is not guaranteed: that studies will be completed as planned, that future results will be consistent with results to date, that retatrutide will prove to be a safe and effective treatment, or that it will receive regulatory approval.

Retatrutide (Eli Lilly)

What it is. Retatrutide is an investigational, once-weekly medicine. Lilly calls it a triple hormone receptor agonist: a single molecule that switches on the body’s receptors for three hormones, GIP, GLP-1 and glucagon.

FDA approval status. Not FDA-approved. Lilly has said it is completing the manufacturing data package and plans to submit retatrutide for US approval in the first quarter of 2027.

The trial program. The Phase 3 program is called TRIUMPH. Phase 3 is the large, late-stage set of trials that usually comes before a company asks FDA for approval. TRIUMPH began in 2023 and enrolled more than 5,800 participants. Across four global registrational trials, it covers obesity or overweight, moderate-to-severe obstructive sleep apnea with obesity, and knee osteoarthritis pain.

Results Lilly has reported.

  • TRIUMPH-4 (December 11, 2025). Adults with obesity or overweight and knee osteoarthritis. Retatrutide lowered weight by up to an average of 28.7% at 68 weeks and reduced a standard knee pain score by up to an average of 75.8%.
  • TRIUMPH-1 (May 21, 2026). Adults with obesity or overweight without diabetes. Average weight loss at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg.
  • TRIUMPH-2 (July 23, 2026). Adults with type 2 diabetes and obesity or overweight. Average weight loss at 80 weeks was 12.7%, 19.1% and 20.8% on the three doses, along with A1C reductions of up to an average of 1.6%. A1C is a blood test that reflects average blood sugar over the past few months.
  • TRIUMPH-3 (July 23, 2026). Adults with severe obesity and established cardiovascular disease. Weight loss of up to an average of 22.6% at 80 weeks. Cardiovascular events were fewer than expected in both groups. The analyses planned in advance gave hazard ratios against placebo of 0.82 on one combined measure and 1.12 on another.
  • TRANSCEND-T2D-2 (October 28, 2026). A separate Phase 3 trial in 1,298 adults with type 2 diabetes, comparing retatrutide head to head with Ozempic 2 mg. At 80 weeks, both retatrutide doses lowered A1C by an average of 2.2%, against 1.8% with Ozempic. Average weight loss was 19.5% on 9 mg and 20.9% on 12 mg, against 9.4% with Ozempic. The trial was open-label, so participants knew which medicine they were taking.

The retatrutide page goes through each trial, including how many people stopped treatment.

CagriSema (Novo Nordisk)

What it is. CagriSema is a once-weekly injection that combines two medicines at a fixed dose. One is cagrilintide, a long-acting amylin receptor agonist. The other is semaglutide, a GLP-1 receptor agonist. Novo Nordisk is studying it for overweight or obesity in the REDEFINE programme and for type 2 diabetes in the REIMAGINE programme.

FDA approval status. Not FDA-approved. Novo Nordisk filed a New Drug Application with FDA for weight management in December 2025, based on the REDEFINE 1 and REDEFINE 2 trials. The company has said: “A decision is expected in Q4 2026.”

Results Novo Nordisk has reported. In REIMAGINE 2, a trial in adults with type 2 diabetes, people treated with CagriSema achieved weight loss of 14.2% after 68 weeks, compared with 10.2% with semaglutide 2.4 mg, if all people adhered to treatment. In 2026 the company also started a Phase 3 trial of a higher-dose version.

The CagriSema page has the trial designs and the reported results.

Orforglipron: approved as Foundayo

Orforglipron is no longer a pipeline drug for weight management. FDA approved it as Foundayo on April 1, 2026. It’s approved for use with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off long term, in adults with obesity, or overweight with at least one weight-related comorbid condition.

One use is still pending. Foundayo is not approved for type 2 diabetes. Lilly has since submitted that use to FDA, but a submission is not an approval.

Because Foundayo is approved, it has a label, a dose schedule and published prices, starting at $149 a month self-pay. The Foundayo guide covers it.

Higher-dose Wegovy and the Wegovy pill

Two Novo Nordisk products have also left the pipeline. Novo Nordisk reported that Wegovy HD, the 7.2 mg dose, launched in the US in April 2026. The US Wegovy label includes it. At 72 weeks in one label study in adults with obesity, average body-weight change was -18.8% with Wegovy 7.2 mg, against -3.9% with placebo and -15.5% with 2.4 mg.

The same company report notes that the European Medicines Agency approved the Wegovy 7.2 mg single-dose pen and the Wegovy pill in July 2026. That’s a European decision. In the US, the Wegovy tablet is already on the label, and the Wegovy guide lists its strengths and prices.

Can I buy retatrutide or CagriSema?

Not through any legal route outside a clinical trial. FDA has said so directly.

  • Compounding is not an option. FDA states: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
  • “Research” products are illegal sales. FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption.” FDA says these have been sold straight to consumers with dosing instructions. It urges consumers not to buy them because they are of unknown quality and may be harmful.

This site does not name, link to or price any seller of these products, and never will. The compounded GLP-1 page explains the rules for compounded drugs in general.

How should I read the trial numbers?

Carefully, for four reasons.

They are topline results from the sponsor. Topline means the first headline numbers, released by the company that runs the trial. A press release is not a label. FDA reviews the full data, and the figures on a label, if one is ever approved, can differ from the headline.

The way of counting changes the number. In TRIUMPH-1, Lilly reported 28.3% average weight loss on 12 mg using the efficacy estimand, which estimates the result if everyone had kept taking the medicine as planned. Counting everyone regardless of adherence (the treatment-regimen estimand), the change on the same dose was -25.0%, against -3.9% on placebo. Both figures come from the same announcement, so check which one a headline is quoting.

“Up to” means the best-performing dose. A phrase like “up to an average of 28.7%” describes the highest dose group, not every participant.

Trials can’t be compared with each other. A 68-week trial in people with knee osteoarthritis and an 80-week trial in people with type 2 diabetes enrolled different people. The same goes for comparing an investigational medicine’s press release with an approved medicine’s label. This site does not rank medicines across separate trials.

Side effects are part of the picture too. In TRIUMPH-1, the share of people who stopped because of adverse events was 4.1%, 6.9% and 11.3% on the 4 mg, 9 mg and 12 mg doses, compared with 4.9% on placebo.

Key dates

  • 2023: The TRIUMPH Phase 3 program for retatrutide begins.
  • December 2025: Novo Nordisk files CagriSema with FDA for weight management. Lilly reports TRIUMPH-4 on December 11.
  • February 2, 2026: Novo Nordisk reports REIMAGINE 2 for CagriSema.
  • April 1, 2026: FDA approves Foundayo (orforglipron).
  • May 21, 2026: Lilly reports TRIUMPH-1.
  • July 23, 2026: Lilly reports TRIUMPH-2 and TRIUMPH-3 and states its plan to submit in the first quarter of 2027.
  • October 28, 2026: Lilly reports TRANSCEND-T2D-2, a head-to-head trial against Ozempic 2 mg.

The company and FDA announce a submission, a decision or new results first. Their own pages are the place to confirm where either medicine stands.

What you can do in the meantime

Waiting for a medicine that may or may not be approved is a choice with a cost, and it’s one to make with your prescriber. Eight FDA-approved GLP-1 medicines are available, with labels, known doses and published prices. The conditions overview lists what each is approved for. The cost guide covers what they cost depending on how you pay, and the cheapest path tool works from your own situation.

Frequently asked questions

Is retatrutide FDA-approved?

No. Lilly calls retatrutide an investigational molecule that cannot be legally sold or marketed for human use, and says there's no guarantee it will receive regulatory approval. FDA says retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.

When will retatrutide be available?

There is no approval or launch date. The only timing the company has given is a plan. Lilly has said it is completing its manufacturing data package and plans to submit retatrutide for US approval in the first quarter of 2027. A submission starts an FDA review. It is not an approval, and we don't predict one.

Is CagriSema FDA-approved?

No. CagriSema is investigational. Novo Nordisk filed a New Drug Application (a request for approval) with FDA for weight management in December 2025, and has said a decision is expected in the fourth quarter of 2026. That's the company's expectation of timing. The decision itself could go either way.

What is the difference between retatrutide and CagriSema?

They are different kinds of medicine from different companies. Retatrutide is Lilly's single molecule that activates the GIP, GLP-1 and glucagon receptors. CagriSema is Novo Nordisk's fixed-dose combination of two medicines: cagrilintide, a long-acting amylin receptor agonist, and semaglutide, a GLP-1 receptor agonist. Both are once-weekly, and both are investigational.

Can I buy retatrutide online or get it compounded?

Not legally. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. FDA has also warned companies that illegally sold unapproved retatrutide falsely labeled for research purposes or not for human consumption. It urges consumers not to buy these products, which are of unknown quality.

Is orforglipron still a pipeline drug?

Not for weight management. FDA approved orforglipron as Foundayo on April 1, 2026 for adults with obesity, or overweight with at least one weight-related comorbid condition. Foundayo is not approved for type 2 diabetes. Lilly has since submitted that use to FDA, but a submission is not an approval.

How much will retatrutide or CagriSema cost?

Nobody outside the companies knows. A medicine has no US price until it is approved and launched. Anyone quoting a price for an investigational medicine is not quoting a legal, FDA-approved product.

How much weight did people lose on retatrutide in trials?

In TRIUMPH-1, Lilly reported average weight loss at 80 weeks of 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg in adults without diabetes, using the efficacy estimand (the result if everyone had kept taking it as planned). Counting everyone regardless of adherence, the figures were -17.6%, -23.7% and -25.0%, against -3.9% on placebo. These are company-reported results, not FDA findings.

What new GLP-1 drugs are in development?

The two people ask about most are retatrutide and CagriSema. Retatrutide is Lilly's once-weekly molecule that activates the GIP, GLP-1 and glucagon receptors. CagriSema is Novo Nordisk's once-weekly combination of cagrilintide and semaglutide. Both are investigational. Orforglipron is off the list: FDA approved it as Foundayo on April 1, 2026.

Sources (24)

  1. 1.
    Eli Lilly: Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
    “In the TRANSCEND-T2D-2 trial, both doses of retatrutide lowered A1C by an average of 2.2% compared to 1.8% with Ozempic at 80 weeks. Participants taking retatrutide lost an average of 44.3 lbs (19.5%; 9 mg) and 47.4 lbs (20.9%; 12 mg) compared to 20.9 lbs (9.4%) with Ozempic. [...] TRANSCEND-T2D-2 (NCT06260722) is a Phase 3, randomized, open-label trial comparing once-weekly retatrutide (9 mg and 12 mg) with once-weekly Ozempic 2 mg in 1,298 adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor.”
  2. 2.
    Eli Lilly: Eli Lilly and Company Form 10-Q for the quarter ended September 30, 2026
    “Submitted orforglipron for type 2 diabetes in the U.S. and Japan.”
  3. 3.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Retatrutide is an investigational, once-weekly, triple hormone receptor agonist. Retatrutide is a single molecule that activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.”
  4. 4.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Retatrutide is an investigational molecule that cannot be legally sold or marketed for human use. [...] Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that retatrutide will prove to be a safe and effective treatment for type 2 diabetes, obesity or other potential indications, that retatrutide will receive regulatory approval, or that Lilly will execute its strategy as expected.”
  5. 5.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
  6. 6.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “The initial TRIUMPH Phase 3 clinical development program is evaluating the safety and efficacy of retatrutide for the treatment of patients with obesity or overweight, moderate-to-severe obstructive sleep apnea and obesity, and knee osteoarthritis pain across four global registrational trials. The program, which began in 2023, enrolled more than 5,800 participants.”
  7. 7.
    Eli Lilly: Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
    “In this global registration trial, where 84.0% of participants had a baseline BMI of ≥35 kg/m², each dose of retatrutide (9 mg and 12 mg) met all primary and key secondary endpoints, delivering significant weight loss and improvements in pain and physical function at 68 weeks using both the efficacy and treatment-regimen estimands. For the co-primary endpoints, retatrutide lowered weight by up to an average of 28.7% (71.2 lbs) and reduced pain by up to an average of 4.5 points (75.8%) using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score.”
  8. 8.
    Eli Lilly: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
    “For the primary endpoint, participants taking retatrutide 9 mg and 12 mg lost an average of 64.4 lbs (25.9%) and 70.3 lbs (28.3%), respectively. Those taking the 4 mg dose of retatrutide, with just a single dose escalation step, lost an average of 47.2 lbs (19.0%). [...] In a pre-specified blinded extension for those with a BMI ≥35, participants who continued on retatrutide 12 mg to 104 weeks lost an average of 85.0 lbs (30.3%).”
  9. 9.
    Eli Lilly: Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
    “Percent change in body weight at 80 weeks: -17.6% (-19.8 kg; -43.7 lbs; 4 mg); -23.7% (-26.7 kg; -58.9 lbs; 9 mg); -25.0% (-28.2 kg; -62.1 lbs; 12 mg) and -3.9% (-4.4 kg; -9.7 lbs; placebo) [...] Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo.”
  10. 10.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “In TRIUMPH-2, all three studied doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and improved glycemic control at 80 weeks in adults with type 2 diabetes and obesity or overweight. Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, alongside A1C reductions of up to an average of 1.6%.”
  11. 11.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “In TRIUMPH-3, both studied doses of retatrutide (9 mg and 12 mg) delivered substantial weight loss in adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. Participants lost up to an average of 55.8 lbs (22.6%) at 80 weeks. In the study, major adverse cardiovascular events (MACE) occurred less frequently than anticipated in both retatrutide and placebo arms. In pre-specified analyses for time to first occurrence of MACE, there were 44 MACE-5 (all-cause death, heart attack, stroke, heart failure event, or coronary revascularization) events observed in participants randomized to retatrutide (pooled 9 mg and 12 mg) and 52 events observed in those randomized to placebo, resulting in a hazard ratio of 0.82 (95.0% CI: 0.55 to 1.22). There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96).”
  12. 12.
    Eli Lilly: Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
    “Lilly is completing the comprehensive Chemistry, Manufacturing, and Controls (CMC) data package required for a Biologics License Application (BLA) and plans to subsequently submit retatrutide in Q1 2027 for U.S. approval.”
  13. 13.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “Once-weekly subcutaneous CagriSema is being investigated by Novo as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment for adults with type 2 diabetes (REIMAGINE programme). CagriSema is a fixed-dose combination of a long-acting amylin receptor agonist, cagrilintide, and a GLP-1 receptor agonist, semaglutide.”
  14. 14.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema for weight management, demonstrating the company's commitment to obesity innovation. A decision is expected in Q4 2026.”
  15. 15.
    Novo Nordisk: Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
    “CagriSema for weight management was submitted to the US FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 pivotal trials.”
  16. 16.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “REDEFINE 1 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg, cagrilintide 2.4 mg and semaglutide 2.4 mg versus placebo in 3,417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. REDEFINE 2 – a 68-week efficacy and safety phase 3 trial of once-weekly CagriSema 2.4 mg/2.4 mg versus placebo in 1,206 adults with type 2 diabetes and either obesity or overweight.”
  17. 17.
    Novo Nordisk: Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
    “When evaluating the effects of treatment, if all people adhered to treatment, and from a mean HbA1c baseline of 8.2%, people treated with CagriSema 2.4 mg/2.4 mg achieved superior HbA1c reduction of 1.91%-points after 68 weeks compared to 1.76%-points with semaglutide 2.4 mg. From a mean baseline body weight of 101 kg, people treated with CagriSema 2.4 mg/2.4 mg achieved superior weight loss of 14.2% after 68 weeks compared to 10.2% with semaglutide 2.4 mg.”
  18. 18.
    Novo Nordisk: Novo’s investigational obesity and diabetes drug CagriSema reduces ‘food noise’ and shows benefits in organ and bone health – EASD 2026
    “CagriSema is Novo Nordisk’s next-generation investigational obesity and diabetes treatment. Novo Nordisk submitted an NDA for obesity to the US FDA and Health Canada in December 2025. In 2026, High-dose CagriSema 2.4 mg/7.2 mg, an efficacy and safety phase 3 trial, was initiated in adults with obesity. [...] In the study, also awarded a Best Abstract Award at EASD 2026, the improvements were also associated with a 22.4% reduction in body weight versus placebo at 52 weeks (estimated treatment difference at 52 weeks, p<0.0001).”
  19. 19.
    FDA: FDA Approves First New Molecular Entity Under National Priority Voucher Program
    “The U.S. Food and Drug Administration today approved Foundayo (orforglipron), marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program. [...] Foundayo is approved for use in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”
  20. 20.
    Eli Lilly: Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
    “Based on these findings, as well as those from ACHIEVE-1 and ACHIEVE-4, Lilly plans to submit Foundayo for the treatment of type 2 diabetes to the U.S. FDA by the end of the second quarter under the Commissioner's National Priority Review Voucher. [...] Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity.”
  21. 21.
    Novo Nordisk: Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook
    “Wegovy® HD was launched in the US in April, and Wegovy® 7.2 mg single-dose pen in the UK in June. [...] Within obesity, Wegovy® 7.2 mg single-dose pen received EMA approval in July based on the STEP UP data providing up to 20.7% mean weight loss. Also within obesity, Wegovy® pill received EMA approval in July based on the OASIS 4 data providing up to 16.6% mean weight loss.”
  22. 22.
    FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 12
    “After 72 weeks of treatment, WEGOVY 7.2 mg injection resulted in a statistically significant reduction in body weight compared with placebo in Studies 8 and 9”
  23. 23.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”
  24. 24.